Sunday, August 04, 2013 9:58:24 AM
China Biotech In Review: China's Rx Market To Total $315 Billion In 2020
Aug 4 2013, 02:35 by: ChinaBio Today | includes: GE, GILD, JNJ, WX 17:13Industry Insights
GlobalData, a London consultancy, projects China's prescription drug market will expand at a 26% compound annual growth rate to $315 billion in 2020, up from $48 billion last year. One of the drivers is China's investment in drug R&D. GlobalData also believes the growth will take place because of (not in spite of) price pressures being exerted by China's government. By increasing affordability, less-expensive products will expand the market and more than make up for lower unit prices, says the company.
Could we classify RapiMeds as a "less-expensive" product which offers "increased affordability"? I think so. SCRC is on the verge of what only a few pharma companies have accomplished. GO SCRC!!!
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM